Theranexus is a publicly listed company that pursued additional financing through an increase of capital, issuing new shares while preserving shareholders’ preferential subscription rights. The subscription period ran from 29 October to 7 November and generated gross proceeds of approximately €7.8 million, the full amount targeted by the company. A total of 1,931,202 new shares were subscribed at a unit price of €1.80. This represented a subscription rate of 44.3 %. The successful raise strengthens Theranexus’ balance sheet and provides fresh capital for its future corporate objectives. No additional operating metrics, product details, or strategic initiatives were disclosed in the article.

Total raised

$9M

Funding rounds

2

Latest round

Equity

Latest activity

Nov 2025